IP
SRNE

Intellectus Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Intellectus Partners’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-557,026
Closed -$2.45M – 559
2018
Q3 		$2.45M Hold
557,026
– – 0.86% 25
2018
Q2 		$4.01M Sell
557,026
-797,422
-59% -$5.42M 1.46% 8
2018
Q1 		$6.97M Sell
1,354,448
-178,000
-12% -$1.27M 2.4% 4
2017
Q4 		$5.82M Sell
1,532,448
-9,447
-0.6% -$24.6K 2.17% 5
2017
Q3 		$2.62M Sell
1,541,895
-43,945
-3% -$80.6K 1.09% 14
2017
Q2 		$3.17M Buy
1,585,840
+490,000
+45% +$956K 1.43% 10
2017
Q1 		$4.33M Sell
1,095,840
-63,425
-5% -$318K 2.2% 3
2016
Q4 		$5.68M Buy
+1,159,265
New +$6.96M 2.95% 4

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Intellectus Partners's SRNE Position: Q4 2018 in Review

Intellectus Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2018, closing a stake of 557,026 shares — an estimated $2.45M sold.

Intellectus Partners first reported a position in SRNE in Q4 2016 and held it in 8 quarters. The position peaked at $6.97M in Q1 2018. 78 funds tracked by Wall St. Rank hold SRNE as of Q4 2018.

  • Intellectus Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 557,026 Sorrento Therapeutics, Inc. shares in Q4 2018, an estimated $2.45M.
  • Intellectus Partners first reported a position in Sorrento Therapeutics, Inc. in Q4 2016 and held it in 8 quarters.
  • Intellectus Partners's Sorrento Therapeutics, Inc. position peaked at $6.97M in Q1 2018.
  • 78 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.